Clinical Pathways (CPs) are increasingly being perceived and used as a tool to improve quality of care, reduce unwarranted variation, and control costs. As their use increases, many challenges and potential barriers to pathway adoption are becoming apparent. The limitations of the current simple rule-based technologies, used to implement CPs often prevent the user from realising full potential of clinical pathways, and contribute to user pushback. Flexible, dynamic and unobtrusive implementation of CPs using cognitive decision-science and artificial intelligence based technologies can help to overcome many of these challenges.
Dr Vivek Patkar CMO, Deontics is talking on Deontics innovative clinical pathway modelling approach at WIN annual conference (24 January 2017) at Warwick university.
Deontics features in Global Digital Health 100 Award List for 2016
We are pleased to be featured in the Global Digital Health 100 Award List for 2016 – turn to page 8 of the Journal of mHealth. Over the past three years, the Global Digital Health 100 has become established as an international benchmark of industry activity for mobile, digital and connected technologies in healthcare
London Mayor Sadiq Khan welcomes Deontics to his International Business Program
Deontics has been announced as one of the latest hi-growth tech companies to join Mayor Sadiq Khan’s International Business Program. The program is designed to select and promote the fastest growing and most promising tech businesses in London. The program will see high growth businesses in the tech world such as Deontics supported at a range of global trade missions and events.
London Mayor Sadiq Khan said “London is one of the most vibrant and diverse places in the world to start and grow a technology business. These high growth companies have the potential to become the next global tech giants and I am delighted that they will join me in showing the world that London is open to talent, business and collaborations.”
Deontics has developed a world leading 4th generation Clinical Decision Support and Adaptive Clinical Pathway technology allowing fully dynamic, real time, implementation of adaptive clinical pathways at the point of care in primary, secondary and tertiary care settings. This improves clinical outcomes and patient safety and simultaneously reduces care costs.
Dr. Guy Wood-Gush, CEO of Deontics, said “Being selected for this program will accelerate our global growth and enable us to reach more customers who are looking to integrate ground breaking AI clinical solutions into their practices and products. London is at the forefront of this technology and we are delighted to be part of this program and to be recognised as leaders in this space.”
LONDON MAYOR’S INTERNATIONAL BUSINESS PROGRAM
The Mayor’s International Business Programme, is a £5m programme part funded by the European Regional Development Fund (ERDF), aims to support high-growth companies in the life sciences, technology and urban sectors to increase their export success across a range of key markets in Europe, Asia and North America.
The three year programme is being led by London & Partners, the Mayor’s official promotional agency, in partnership with KPMG, PA Consulting, BDO, Benoy and London Chamber of Commerce and Industry.
For more information on Deontics contact Guy Wood-Gush, email@example.com, or visit our website, www.deontics.com
Nick Beard appointed non-executive director at Deontics
Artificial intelligence health company adds board member to promote growth in evidence-based and personalised medicine markets in US and UK markets
London – 12th October: Clinically-led artificial intelligence (AI) company Deontics has announced Nick Beard as a non-executive director, adding to its growing pool of strategic health, science, and technology expertise.
Beard is a physician and former hospital chief information officer. Over a 30 year career, he has held numerous senior executive positions at leading electronic health records and clinical guidelines companies in both the US and UK. He will work closely with the Deontics executive team to help shape the future strategy of the company and the marketing of its state-of-the-art clinical pathways and decision modelling products into payer, provider and B2B healthcare IT markets.
The company provides pioneering AI technology which acts as a clinical ‘sat nav’ by integrating evidence-based guidelines with individual patient data, providing dynamic, personalised treatment recommendations at the point of care.
Commenting on the appointment, Dr. Guy Wood-Gush, CEO of Deontics said: “Nick brings a long history of industrial and academic experience across healthcare informatics and clinical guidelines, and will contribute materially towards the further development of our company. This is a significant appointment at a positive time in our growth.”
Based in Seattle, Nick was SVP of Strategy at Milliman Care Guidelines, sold to the Hearst Corporation; CMO at the Healthy Communities Institute, sold to Xerox Corporation, and CMO and VP of health informatics and product marketing at IDX, which was sold to GE for $1.2bn. While at IDX, Nick was the principal investigator on the SAGE project, working to develop a universal clinical pathways technology; collaborating with leading centres, Stanford University, the Mayo Clinic, the University of Nebraska and Intermountain Healthcare.
“I believe Deontics can become the technology of choice for organisations that work to disseminate clinical best practice in a way that fully leverages the spread of electronic health records,” said Beard. “This position is at the heart of what I have been working on for most of my career. Deontics has the right technology, talent and vision of where the industry needs to go next to deliver personalised, evidence-based care.”
Beard added: “UK and US health industries share the challenge of producing high quality, affordable care. Delivering clinical best practice while managing cost is often seen as a dichotomy. However, by putting evidence-based clinical guidance into the hands of clinicians, costs of care are often lower while outcomes are improved. This is what Deontics can support, for clinicians and patients.”
This appointment is the latest milestone for the company since it spun-out of the University of Oxford, University College London and Cancer Research UK just two years ago. Deontics is already delivering new pathways for large NHS trusts, has built a lung cancer system for a global pharmaceutical company, and is supplying technology to several leading international IT companies.
Beard’s teaching experience has seen him lecture on clinical informatics across the globe at Stanford University’s Medical Informatics Department, the University of Washington, the National University of Singapore, and Glasgow University. He is currently assistant clinical professor at Oregon Health & Science University, and regularly lectures at the University of California at Berkeley.
Beard qualified in medicine at St George’s Medical School, London, and has a Masters of Science degree in software engineering from Imperial College.
For more information on Deontics, visit: www.deontics.com
Deontics provides personalised clinical decision support software that is the result of long-term academic research in medical artificial intelligence (AI) originating at Carnegie Mellon University, and subsequently developed at the Medical Research Council, University of Oxford, University College London and Cancer Research UK.
Deontics was founded to incorporate concepts rooted in cognitive science, AI and medical informatics into day-to-day clinical decision making in order to improve the quality of medical care in the UK and throughout the world.
Deontics provides clinically-led AI for healthcare providers, payers and patients that delivers personalised clinical decision support for quality patient outcomes. A clinical ‘sat nav’ for personalised care, it integrates clinical good practice at national and local level with individual patient information directly into the patient pathway in a visually effective user interface. Use of Deontics systems throughout a network of hospitals and primary care clinicians can greatly enhance the quality of integrated care as well as the quality of individual specific clinical decisions.
Chris Marsom, Highland Marketing (on behalf of Deontics)
Tel: +44 (0) 1877 332719
Mob: + (0) 7788 393985
For further information contact:
Dr. Guy Wood-Gush, CEO, Deontics Ltd.
Tel: +44 (0) 7725 333835
Deontics announced as a finalist at the Patient Safety Awards 2016
Clinically-led artificial intelligence (AI) company Deontics has been announced as a finalist at the Patient Safety Awards 2016 in the ‘Best Emerging Technology and IT’ category.
Deontics impressed judges with its pioneering AI technology which acts as a clinical ‘sat nav’ for personalised care by integrating clinical evidence-based practice at national and local level with individual patient information directly into the patient pathway in a visually effective user interface.
Its state-of- the-art computer modelling language system provides clinicians with suggestions to support and justify clinical decisions at the point-of- care, and helps to better coordinate care delivery through alerts, reminders, clinical pathways and workflow management.
The awards, now in their 8 th year, drew praise from judges on the high quality of entries. The second round of judging will take place next week, and will see experts from the Deontics team present to a panel of senior and influential figures from the health sector. The winner will be announced on 5th July 2016 at an awards ceremony, to be held in Manchester Central alongside the Patient Safety Congress.
There were over 650 submissions, of which 170 made it to the final cut, which means that there is fierce competition for these coveted awards. They are run by HSJ and Nursing Times, whose respective editors Alastair McLellan, and Jenni Middleton, said: “The projects submitted demonstrate those who are constantly innovating and overcoming challenges to put patients’ needs first.”
The announcement as an awards finalist represents another milestone in the company’s rise since in span out of the University of Oxford, University College London and Cancer Research UK just two years ago. Deontics is already delivering new pathways for large NHS trusts, has built a lung cancer system for a global pharmaceutical company, and is in commercial discussions with several leading IT companies.
Feedback from clinicians, patients and providers has highlighted the role Deontics plays in supporting safer care. The technology helps to avoid decision-making errors and ensure performance standardisation across medicine – a key recommendation in the UK’s National Information Board (NIB) framework, Personalised Health and Care 2020 (PHaC 2020). The report references the need to “drive down variations in quality and safety of care, patients’ changing needs will go unmet, people will be harmed who should have been cured, and unacceptable variations in outcomes will persist”.
Dr. Guy Wood-Gush, CEO of Deontics said: “Unwarranted variability in clinical practice is a well- known phenomenon which can lead to unnecessary deaths and patient morbidity. Being named a finalist at the Patient Safety Awards is another step in our mission to help make personalised health and care a reality.
“The NHS is going through a period of reform and there is now increasing recognition that reducing variation through consistent and configurable local pathways is a way to improve patient experience, reduce waiting times and reduce costs by preventing avoidable readmissions reducing lengths of stay and preventing error”, continued Dr. Wood-Gush.
Deontics provides personalised clinical decision support software that is the result of long-term academic research in medical artificial intelligence originating at Carnegie Mellon University, and subsequently developed at the Medical Research Council, University of Oxford, University College London and Cancer Research UK.
Deontics was founded to incorporate concepts rooted in cognitive science, artificial intelligence and medical informatics into day-to- day clinical decision making in order to improve the quality of medical care in the UK and throughout the world.
Deontics provides clinically-led artificial intelligence for healthcare providers that delivers personalised clinical decision support for quality patient outcomes. A clinical ‘sat nav’ for personalised care, it integrates clinical good practice at national and local level with individual patient information directly into the patient pathway in a visually effective user interface. Use of Deontics systems throughout a network of hospitals and primary care clinicians can greatly enhance the quality of integrated care as well as the quality of individual specific clinical decisions.